COMPASS Pathways plc
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CMPS | CMPX | HELP | TRAX | RAPP | ACHV | |
|---|---|---|---|---|---|---|
| Market cap | 1.22B | 137.35M | 634.16M | 2.06B | 1.50B | 719.66M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -6.0 | -1.4 | -4.9 | -13.6 | -5.1 | -10.7 |
| Price/book | 8.6 | 0.8 | 2.2 | 10.3 | 3.2 | -48.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +56.47% | −80.29% | +51.76% | +143.89% | −2.79% | +36.51% |
| Today | +0.12% | +1.29% | −3.88% | +5.83% | +1.93% | +3.71% |
The closest companies by business and industry (Medical Care Facilities). Prices may be delayed up to 15 min.
Latest news
All CMPS news ›Compass Pathways: 3 Key Takeaways for Long-Term Investors
Its clinic network of more than 8,500 interventional psychiatry centers gives COMP360 a ready path to patients once approved. COMPASS is preparing for the potential commercial launch of COMP360 by leveraging existing interventional…
Compass Pathways Q3 Earnings Call Highlights
Posted by Sarita Garza on Nov 4th, 2026 Compass Pathways (NASDAQ:CMPS) said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within…
More from 1 other outlet
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights
LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)-- Compass Pathways plc (CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today reported the third quarter 2026 financial results…
Compass Pathways reports US$444M cash and runway into 2028
The psilocybin developer expects its final application submission within two weeks, with a launch targeted for the first half of 2027. Cash is expected to fund operations into 2028 as Compass Pathways plc NASDAQCMPS reported US$444 million…
COMPASS Pathways rebounds on earnings after selloff driven by rival’s NDA submission
Compass Pathways (CMPS) stock rebounds after Q3 results calm launch fears over psilocybin compound COMP360 as Usona completes FDA filings first. Read more here. Yarygin/iStock via Getty Images Following a sharp selloff in the previous…
Compass Pathways To Complete COMP360 FDA Filing Within Two Weeks — CEO Nath Eyes Launch In First Half Of 2027
Compass Pathways (CMPS) was on investors’ radar on Tuesday, after the company said it expects to complete its New Drug Application for its depression treatment within two weeks, potentially paving the way for a commercial launch in the…
COMPASS Pathways ADS GAAP EPS of -$0.31 beats by $0.10
Compass Pathways Q3 earnings beat estimates as cash jumps to $444M. - COMPASS Pathways ADS press release (CMPS): Q3 GAAP EPS of -$0.31 beats by $0.10. - Cash and cash equivalents were $444.0 million as of September 30, 2026, compared with…
COMPASS Pathways - American Depository Shares Stock 12‑Month Price Target Cut to $23.18, Implies 176% Upside
TradingView COMPASS Pathways - American Depository Shares Stock 12‑Month Price Target Cut to $23.18, Implies 176% Upside - According to estimates from 17 analysts, COMPASS Pathways Plc - Ame
Compass Pathways stock closes down 27.31% at $8.41, below key averages
Compass Pathways stock (CMPS) closed at $8.41 on Monday, November 2, 2026, below its daily exponential averages and its lower Bollinger band… Compass Pathways stock (CMPS) closed at $8.41 on Monday, November 2, 2026, below its daily…
Compass to submit psilocybin depression drug for approval imminently after stock wobbles
Compass Pathways expects to finalize a rolling submission for its highly anticipated psilocybin depression drug “in the next two weeks,” the company said Tuesday, possibly providing a balm for investors after its stock dipped Monday…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com8
- seekingalpha.com7
- fool.com3
- headynj.com2
- stocktitan.net2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 32 articles, not a forecast.